drugset / Trial / NCT00017381

Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma

NCT00017381

Phase 0 Completed 30 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial is studying how well monoclonal antibody therapy with peripheral stem cell transplant works in treating patients with non-Hodgkin's lymphoma. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Peripheral stem cell transplant may allow the doctor to give higher doses of monoclonal antibodies and kill more cancer cells

Timeline

Start
2001-04
Primary completion
2007-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Rituximab Monoclonal antibody Intravenous
Background Cyclophosphamide Other / unclassified Intravenous
Background filgrastim Protein / enzyme biologic Subcutaneous